News and Trends 26 Mar 2018 New Antibiotic for Urinary Tract Infections Gets Positive Phase II Results Allecra Therapeutics has obtained positive Phase II study results for its new urinary tract infection antibiotic, supporting the launch of a Phase III trial. Allecra Therapeutics, a French-German biotech, has obtained positive Phase II trial results for its lead antibiotic candidate for treating urinary tract infections. The drug, AAU101, was given to patients intravenously with cefepemine, another antibiotic […] March 26, 2018 - 1 minutemin - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 22 Mar 2018 French Biotech Signs a Deal to Fight Antibiotic Resistance Deinove is licensing a portfolio of antibiotics for multi-drug resistant bacteria from Redx Pharma. Deinove, based in Montpellier, France, has signed an agreement to use synthetic molecules developed by UK biotech Redx to treat lethal anitbiotic-resistant infections. Redx’s molecules are a new class of antibiotics targeting an enzyme involved in bacterial DNA replication in Gram-negative bacteria. Deinove plans to […] March 22, 2018 - 1 minutemin - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 15 Mar 2018 New Antibiotic for MRSA Infections is Ready for US Clinical Trials Update (15/03/2018): The FDA has granted Fast Track Designation to XF-73, an antibody being developed by Destiny Pharma against post-surgical MRSA infections. Originally published on 26/02/2018 Destiny Pharma’s antibiotic for post-surgical infections will begin its clinical development after the FDA accepted its Investigational New Drug application. Destiny Pharma wants to combat the growing antibiotic resistance […] March 15, 2018 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
More News! 8 Mar 2018 Evotec Takes Over Sanofi’s Infectious Disease Pipeline Evotec will be getting over 10 assets, €60M upfront and about 100 scientists from Sanofi’s infectious disease research unit to work on developing new antimicrobials. Evotec has entered exclusive negotiations with Sanofi to accelerate infectious disease R&D through a new innovation platform located near Lyon, France, that will be open to academia, private companies, foundations and government agencies. Sanofi, […] March 8, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 28 Feb 2018 Novo Holdings Pumps €135M into New Antibiotic Development to Fight Resistance Novo Holdings has launched a $165M (€135M) impact fund to support companies that are developing new drugs to overcome antibiotic resistance. Novo Holdings manages the assets of the Novo Nordisk Foundation, which invests money in companies that are working on scientific, humanitarian, and social projects. The company has launched a fund to develop new treatments for infections […] February 28, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 13 Feb 2018 High-Speed Healing Could Prevent the Infection of Chronic Wounds Swedish scientists have used bacteria to deliver a chemical into wounds that speeds up the healing process. This could help to prevent their infection with dangerous strains of resistant bacteria. Researchers at Uppsala University have identified a technique to accelerate the wound healing process and reduce the chance of infection. The study, published in PNAS, […] February 13, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 10 Feb 2018 Superbugs: Fighting Antibiotic Resistance at the Science Museum An exhibition at the Science Museum London features some of the deadliest superbugs on Earth and the stories of the people fighting against the threat of antibiotic resistance. It is estimated that, by 2050, 10 million people will die every year due to infections with antibiotic-resistant bacteria. Meaning that the numbers will be higher than […] February 10, 2018 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 5 Feb 2018 A DNA-Based Diagnostic Company Rakes in £1.8M to Combat Antimicrobial Resistance A new molecular diagnostics company, LIG Biowise, has just closed a £1.8M Series A fundraising round in its effort to combat antimicrobial resistance. Based in Manchester, LIG Biowise, is working on a DNA-based diagnostic to catch antibiotic resistant infections early. The company has now closed a Series A of £1.8M (€2.0M), led by Hong Kong-based Phoenix Bridge, to fund […] February 5, 2018 - 1 minutemin - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 24 Jan 2018 Biotech and Pharma Boost R&D and Slow Sales to Beat Antibiotic Resistance To fight antibiotic resistance, the independent report found that companies are developing new drugs, discouraging their overselling, limiting their run-off into wastewater, and tracking the spread of superbugs. Antibiotics are becoming ineffective at an alarming rate due to our misuse in healthcare, animals, and crops. Antibiotic resistance is responsible for 700,000 deaths each year, which is expected to continue […] January 24, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 16 Jan 2018 This French Biotech’s Medical Device Protects Against Antibiotic Resistance Da Volterra has achieved impressive early results with its antibiotic resistance-busting medical device by successfully protecting the diversity of the microbiome. French biotech Da Volterra is developing products to fight the rapidly rising rates of antibiotic resistance. During a Phase I study, the company’s medical device, DAV132, was used with the antibiotic, moxifloxacin, and successfully protected the intestinal […] January 16, 2018 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 8 Jan 2018 This Skin Patch Could Slow the Rate of Antibiotic Resistance Researchers have developed a skin patch that delivers drugs directly into the blood, avoiding the gut which is a breeding ground for antibiotic resistance. Researchers at Queen’s University Belfast are developing a skin patch to deliver drugs through the skin and directly into the bloodstream via thousands of ‘microneedles’. The technology is being tested as a […] January 8, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
More News! 21 Dec 2017 Oxford Biotech Makes a Latin American Deal for Its Antibiotic In a deal worth up to €23.6M, Summit Therapeutics licensed the commercialization of its new antibiotic ridinilazole to Eurofarma. Oxford-based Summit Therapeutics is working on new antibiotics to fight antimicrobial resistance. Its candidate ridinilazole has attracted the attention of a Brazilian pharma, Eurofarma, and the pair has made a deal for $2.5M (€2.1M) upfront and […] December 21, 2017 - 1 minutemin - By Evelyn Warner Share WhatsApp Twitter Linkedin Email